Hoe verhoudt MDGL's PB Ratio zich tot zijn concurrenten?

MDGL is duur op basis van de Price-To-Book -ratio ( 8.9 x) vergeleken met het gemiddelde van de peer ( 5.3 x).

Hoe verhoudt MDGL's PB Ratio zich tot andere bedrijven in de US Biotechs industrie?

MDGL is duur op basis van de Price-To-Book -ratio ( 8.9 x) vergeleken met het US Biotechs -industriegemiddelde ( 1.8 x).

Wat is MDGL's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { MDGL te berekenen voor waarderinganalyse.

Wat is de reële prijs van MDGL als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

MDGL ( $317.09 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $1918.23 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

Madrigal Pharmaceuticals (Nasdaq:MDGL) - Aandelenkoers, Nieuws & Analyse

MDGL Overzicht aandelen

MDGL fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 83.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 73.08% per jaar groeien

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Volatiele aandelenkoers in de afgelopen 3 maanden

Madrigal Pharmaceuticals, Inc. Concurrenten

Krystal Biotech

NasdaqGS:KRYS

US$5.1b

Iovance Biotherapeutics

NasdaqGM:IOVA

US$2.5b

Arcellx

NasdaqGS:ACLX

US$4.7b

Day One Biopharmaceuticals

NasdaqGS:DAWN

US$1.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Madrigal Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$317.09
52 Week Hoogtepunt	US$368.29
52 Week Laag	US$168.25
Bèta	-0.47
11 maand verandering	51.80%
3 maanden verandering	27.51%
1 Jaar Verandering	66.47%
33 jaar verandering	272.43%
5 jaar verandering	187.19%
Verandering sinds IPO	3,024.01%

Recent nieuws en updates

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Nov 03

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Nov 02

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 24

Recent updates

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Nov 03

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Nov 02

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 24

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

Aug 09

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dec 20

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Aug 05

Madrigal: Buy And Hoard Before Q4 Data Readout

Aug 04

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Jul 08

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Rendement voor aandeelhouders

	MDGL	US Biotechs	US Markt
7D	0.6%	-6.5%	-1.0%
1Y	66.5%	14.6%	30.3%

Rendement versus industrie: MDGL overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 14.6 % opleverde.

Rendement versus markt: MDGL overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.3 %.

Prijsvolatiliteit

Is MDGL's price volatile compared to industry and market?
MDGL volatility
MDGL Average Weekly Movement	10.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van MDGL is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van MDGL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	376	Bill Sibold	www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van therapeutica voor de behandeling van niet-alcoholische steatohepatitis (NASH) in de Verenigde Staten. De belangrijkste productkandidaat is resmetirom, een op de lever gerichte thyroïde hormoonreceptor bèta-agonist, die zich in Fase 3 van het klinisch onderzoek bevindt voor de behandeling van NASH. Het bedrijf heeft zijn hoofdkantoor in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Madrigal Pharmaceuticals zich tot de beurswaarde?
MDGL fundamentele statistieken
Marktkapitalisatie	US$6.85b
Inkomsten(TTM)	-US$518.67m
Inkomsten(TTM)	US$76.81m

90.0x

P/S-verhouding

-13.3x

Koers/Winstverhouding

Is MDGL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MDGL resultatenrekening (TTM)
Inkomsten	US$76.81m
Kosten van inkomsten	US$2.79m
Brutowinst	US$74.03m
Overige uitgaven	US$592.70m
Inkomsten	-US$518.67m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-23.78
Brutomarge	96.37%
Nettowinstmarge	-675.24%
Schuld/Eigen Vermogen Verhouding	15.1%

Hoe presteerde MDGL op de lange termijn?

Bekijk historische prestaties en vergelijking

MDGL Overzicht aandelen

Beloningen

Risicoanalyse

Madrigal Pharmaceuticals, Inc. Concurrenten

NasdaqGS:KRYS

US$5.1b

NasdaqGM:IOVA

US$2.5b

NasdaqGS:ACLX

US$4.7b

NasdaqGS:DAWN

US$1.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Forecast to breakeven in 2026

Consensus revenue estimates increase by 59%

Independent Director notifies of intention to sell stock

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Recent updates

Forecast to breakeven in 2026

Consensus revenue estimates increase by 59%

Independent Director notifies of intention to sell stock

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 34%, EPS downgraded

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis